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Abstract
Introduction: Early diagnosis of 2019-nCoV infection is of great importance and can be challenging in psychiatric patients, espe-
cially when a mental illness such as somatoform disorder causes one or more bodily symptoms because the clinical features of this
group of patients may be more confusing compared with non-psychiatric patients. On the other hand, treating this infection in
psychiatric patients faces some challenges.
Case Presentation: A case of the 2019-nCoV infection is reported in a patient who was admitted to the psychosomatic ward with
a diagnosis of somatic symptom disorder. The patient had a history of numerous unexplained physical complaints, usually com-
plained of some new physical symptoms when informed of the time of his discharge. Although the possibility of misdiagnosis was
high, based on examinations and some paraclinical evaluations, the patient underwent a simultaneous diagnosis of COVID-19. Un-
like usual, he did not complain of any new physical complaints after informing of the 2019-nCoV infection and was willing to be
discharged. Some diagnostic and therapeutic challenges regarding 2019-nCoV infection in the patient were examined.
Conclusions: There are three clinically relevant learning points to be noted from this case report. Firstly, the importance of paying
attention to the patient’s complaints in any mental patient, even disorders related to unexplained physical complaints. Secondly,
the introduction highlights the differences in the care of patients with COVID-19 between psychiatric and non-psychiatric patients
and the need for a multidisciplinary approach. Third, this introduction identifies a crucial diagnostic role for CT thorax in symp-
tomatic patients with suspected COVID-19 because the false-negative rate with RT-PCR COVID-19 nasopharyngeal swabs is high.
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1. Introduction
According to the fifth edition of the American Psy-
chiatric Association’s Diagnostic and Statistical Manual of
Mental Disorders (DSM-5), somatic symptom disorder is di-
agnosed when one or more persistent somatic symptoms
which are associated with excessive thoughts, feelings, and
behaviors related to those symptoms were present (1, 2).
Physicians face various challenges in diagnosing and treat-
ing these patients and find it difficult to treat this group of
patients (2, 3). The introduction of this case explains the
diagnostic and therapeutic challenges of 2019-nCoV infec-
tion (COVID-19) in a patient admitted to the hospital with a
diagnosis of somatic symptoms disorder.
2. Case Presentation
A 31-year-old single man was admitted to the psycho-
somatic ward due to suicidal thoughts, self-cutting, and
outbursts of anger after arguing with family members. He
complained of severe insomnia and some physical symp-
toms, including severe headache, burning of the head,
and dizziness despite adherence to the medication (ser-
traline 100 mg per day and olanzapine 10 mg at bed-
time). Psychiatric interviews revealed that since the last
2 years following an emotional stressor, he has suffered
from abdominal pain, hurt burn, nausea, and body pain,
which has led to his frequent hospitalizations on the in-
ternal medicine and psychosomatic floor. Along with
these symptoms, he frequently suffered from depressed
mood, insomnia, loss of appetite, hopelessness, irritabil-
ity, the thought of death, and interpersonal dysfunction
over the past two years. At times, although the patient be-
came asymptomatic e.g., gastrointestinal symptoms were
relieved some days when his mood was euthymic, gastroin-
testinal symptoms quickly appeared upon experiencing
new stressors or recalling previous stress. The patient has
never had a history of physical aggression, no history of
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substance abuse, and the exam of his urine test for sub-
stance was negative. He left the job nine months ago due
to severe gastrointestinal symptoms. Medical examina-
tions and paraclinical assessments, including endoscopy,
colonoscopy, and laboratory tests, were performed, but all
were reported as normal. Brain CT scans and electroen-
cephalogram did not show abnormal findings, and no ev-
idence of memory impairment was found through clini-
cal cognitive assessments. The patient did not have evi-
dence for the episode of mania or psychosis and based on a
dual diagnosis of the somatic symptom disorders and ad-
justment disorder with depressed mood, sertraline 100 mg
daily, olanzapine 5 mg three times daily, gabapentin 300
mg twice a day, and clonazepam 1 mg at bedtime were ad-
ministrated.
The day after his admission, he complained of acute
abdominal and chest pain. Chest X-rays, electrocardio-
gram, abdominal ultrasound, and laboratory examina-
tion, including myocardial enzymes, were examined. The
results of paraclinical examinations were normal, except
for liver enzymes that had doubled; levels of alanine
aminotransferase, aspartate aminotransferase, and alka-
line phosphatase were 129, 96, and 268 IU per liter, re-
spectively; so the doses of sertraline, gabapentin, olanza-
pine, and clonazepam were reduced. Repetition of liver
enzymes after seven days showed a decrease. He received
several sessions of supportive psychotherapy because he
did not have the skills to deal with acute stressors. Despite
the reduction in drug dose, a significant improvement was
observed in depressive symptoms, suicidal ideation, and
physical symptoms.
The day that discharge planning was announced to
the patient, he complained of a sore throat for the last
two nights, without any other symptoms of COVID-19-like
respiratory distress, shortness of breath or chest pain,
cough, rhinorrhea, fever, muscle pain, and so on. Physi-
cal Examination showed erythema and some exudate in
the throat, but the lungs were clear and vital signs were
within normal ranges. Amoxicillin 500 mg every 8 hours
was administered, and due to the concomitant pandemic
of COVID-19, some laboratory evaluations were requested
as an emergency. To avoid the potential risk of transmit-
ting infectious disease, the patient was transferred to an
isolated room, and emergent infectious consultation was
requested.
Pulse oximetry showed PO2 saturation as 96%. The
patient’s new laboratory findings suggested an infection:
WBC = 9,900 /mm3, L = 18%, Hb = 16.6 g/dL, PLT = 289,000
/mm3 and CRP = 26 mg/L. The lung CT scan showed patchy
multifocal multilobed pulmonary involvement in favor
of COVID pulmonary involvement. The infectious dis-
ease specialist made a diagnosis of 2019-nCoV infection
for the patient and recommended real-time polymerase-
chain-reaction (RT-PCR) COVID-19 testing and initiation of
treatment. The next day patient was discharged from
the hospital, but some interventions were performed be-
fore discharge. He received a levofloxacin injection. Also,
azithromycin 500 mg daily, hydroxychloroquine 200 mg
every 12 hours was prescribed to use following discharge.
Corrected QT Interval (QTC) was within the normal range,
but considering the possibility of the emergence of res-
piratory distress and some drug interactions, the dose of
clonazepam, gabapentin, and olanzapine was reduced be-
fore discharge. A training session was held to learn the
principles of quarantine, symptoms indicating the sever-
ity of the disease, and the process of follow-up treatment.
A nasopharyngeal swab was taken before discharge, al-
though a negative result for 2019-nCoV by RT-PCR assay
was obtained two days after discharge. Because it takes
about 48 hours to find the result for 2019-nCoV by RT-PCR
assay, and in many cases, this test has false-negative re-
sults, many physicians diagnose 2019-nCoV infection in
Iran based on the patient’s symptoms and the results of
non-specific tests such as CBC, CRP, especially evidence of
the lung involvement with Coronavirus on CT scans.
3. Discussion
Psychiatric disorders, especially somatic symptom dis-
order, can interfere with the care of patients infected with
the 2019-nCoV. These patients may report unexplained res-
piratory and other symptoms of COVID-19 after being in-
formed of their infection, or conversely, may focus on other
physical or mental symptoms and do not pay adequate at-
tention to more important symptoms. On the other hand,
the patients may experience an exacerbation of the pri-
mary disorder in the face of new stress, especially patients
who did not have adequate defense mechanisms and intel-
lectual function. Another issue that should be considered
in mentally ill patients is that the patient may not have suf-
ficient insight into the importance of using protective ma-
terials and social distance, leading to the transmission of
the disease to others.
Psychiatric drugs have different physical side effects
that should be considered in patients with COVID-19. Se-
lective serotonin reuptake inhibitors (SSRIs) like sertraline
can cause slowing of heart rate, sinus bradycardia, or si-
nus arrest (4, 5). Some antipsychotics are associated with
QT interval prolongation, and if they are taken with other
drugs such as azithromycin or chloroquine, which have
the same risk, the risk of QT prolongation is further in-
creased and can lead to be fatal ventricular arrhythmia (6-
8). Benzodiazepines can cause respiratory depression, so
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short-acting benzodiazepines with the lowest dose are rec-
ommended if necessary (6, 9). Given that most psychiatric
drugs have hepatic metabolism and they may inhibit the
hepatic metabolism of other medications, it is essential to
pay attention to the drug interaction of psychiatric medi-
cation with some of the drugs that commonly are used in
COVID-19 (6, 10). In this patient, due to the recent increase
in liver enzymes, there was a need to pay more attention to
this issue, and liver enzyme tests were repeated.
One important issue is the psychological effects that
an infected patient has on other patients. If other patients
inform that a patient who was hospitalized at the same
time is infected with coronavirus, they may become wor-
ried and anxious. Stigma is an important issue in both
psychiatric disorders and infectious diseases. Stigma can
lead to a social distance of the infected person from others.
This type of behavior change can prevent the disease from
spreading (11). However, stigma can prevent healthy behav-
iors and lead to disease severity, disease transmission, and
problems in controlling the spread of infectious diseases
(12). Although the patient always tried to attract the atten-
tion of others and play the role of the patient by expressing
physical complaints, he was upset about his infection with
COVID and did not want other patients to know about his
infection.
Another issue that may be helpful in the recent pan-
demic is the crucial diagnostic role for thoracic CT scan in
symptomatic patients who are suspected of COVID-19 since
the false-negative rate with RT-PCR COVID-19 nasopharyn-
geal swabs is as high as 25% - 30% (13).
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